• Molecular NameDroxidopa
  • SynonymDroxydopa; L-dihydroxyphenylserine; L-DOPS; L-threo-3,4-dihydroxyphenylserine
  • Weight213.189
  • Drugbank_IDDB06262
  • ACS_NO23651-95-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-3.27
  • pkaN/A
  • LogD (pH=7, predicted)-3.28
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.13
  • LogSw (predicted, AB/LogsW2.0)44.65
  • Sw (mg/ml) (predicted, ACD/Labs)1.56
  • No.of HBond Donors6
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds3
  • TPSA124.01
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA psychoactive drug and synthetic amino acid precursor which acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
  • Absorption_valueN/A
  • Absorption (description)Absorption of droxidopa is relatively slow after oral administration
  • Caco_2N/A
  • Bioavailability90.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is converted to (–)-noradrenaline [(–)-norepinephrine] by aromatic L-amino acid decarboxylase, which is distributed in various tissues including the peripheral sympathetic nerves. Maximum plasma concentration is reached after 3 h.
  • Half life1.5 h
  • ExcretionIt is excreted in urine unchanged (20% of an oral dose is recovered within 12 h of administration) and as noradrenaline (norepinephrine), with approx. 1.5% of a dose being recovered over 24 h.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityWith close to 20 years on the market, L-DOPS has proven to have very few side effects of which most are mild. Patients have reported tachycardia, hypertension, nausea and vomiting, and headache or migraine.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A